Effectiveness of Incretin Agonists in Autoimmune and Metabolic Disorders։ A Literature Review

ABSTRACT

Aim: To summarize the current literature data on the mechanism of action of incretin agonists (IA) on the metabolism of patients with autoimmune thyroiditis and morbid obesity, based on the analysis and generalization of data obtained from the studies reviewed.

Results: The analysis of the available literature (comprising over 80 scientific papers, predominantly published within the last 5 years) indicates that the findings regarding the effects of IAs on the course of thyroiditis and metabolic activity in this patient population across different cohorts remain highly contradictory. This underscores the necessity for further in-depth exploration of the mechanisms through which these agents influence both the primary pathology and its associated comorbidities. Furthermore, numerous aspects of combination therapy involving IAs and components of autoimmune thyroiditis treatment remain inadequately studied.

Conclusion: There is an essential need to identify strategies for optimizing the management of this patient group. In particular, targeted research examining the effects of various classes of IAs on the metabolism of patients with autoimmune thyroiditis, obesity, and obstructive sleep apnea syndrome would significantly contribute to the development and implementation of optimized management strategies for this patient cohort.